|
1.
|
Aggarwal BB and Sung B: Pharmacological
basis for the role of curcumin in chronic diseases: an age-old
spice with modern targets. Trends Pharmacol Sci. 30:85–94. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Sung B, Prasad S, Yadav VR and Aggarwal
BB: Cancer cell signaling pathways targeted by spice-derived
nutraceuticals. Nutr Cancer. 64:173–197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Shehzad A, Wahid F and Lee YS: Curcumin in
cancer chemoprevention: molecular targets, pharmacokinetics,
bioavailability, and clinical trials. Arch Pharm (Weinheim).
343:489–499. 2010. View Article : Google Scholar
|
|
4.
|
Pan MH, Huang TM and Lin JK:
Biotransformation of curcumin through reduction and glucuronidation
in mice. Drug Metab Dispos. 27:486–494. 1999.PubMed/NCBI
|
|
5.
|
Ireson C, Orr S, Jones DJ, Verschoyle R,
Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward
WP and Gescher A: Characterization of metabolites of the
chemopreventive agent curcumin in human and rat hepatocytes and in
the rat in vivo and evaluation of their ability to inhibit phorbol
ester-induced prostaglandin E2 production. Cancer Res.
61:1058–1064. 2001.
|
|
6.
|
Huang MT, Wand ZY, Georgiadis CA, Laskin
JD and Conney AH: Inhibitory effects of curcumin on tumor
initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene.
Carcinogenesis. 13:2183–2186. 1992.
|
|
7.
|
Huang MT, Smart RC, Wong CQ and Conney AH:
Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and
ferulic acid on tumor promotion in mouse skin by
12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 48:5941–5946.
1988.
|
|
8.
|
Huang MT, Lou YR, Ma W, Newmark HL, Reuhl
KR and Conney AH: Inhibitory effects of dietary curcumin on
fore-stomach, duodenal, and colon carcinogenesis in mice. Cancer
Res. 54:5841–5847. 1994.PubMed/NCBI
|
|
9.
|
Inano H, Onoda M, Inafuku N, Kubota M,
Kamada Y, Osawa T, Kobayashi H and Wakabayashi K: Potent preventive
action of curcumin on radiation-induced initiation of mammary
tumorigenesis in rats. Carcinogenesis. 21:1835–1841. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Inano H, Onoda M, Inafuku N, Kubota M,
Kamada Y, Osawa T, Kobayashi H and Wakabayashi K: Chemoprevention
by curcumin during the promotion stage of tumorigenesis of mammary
gland in rats irradiated with γ-rays. Carcinogenesis. 20:1011–1018.
1999.PubMed/NCBI
|
|
11.
|
Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin
JK, Lai GM, Hsieh CY and Cheng AL: Curcumin-containing diet
inhibits diethylnitrosamine-induced murine hepatocarcinogenesis.
Carcinogenesis. 21:331–335. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Aggarwal BB, Shishodia S, Takada Y,
Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin
suppresses the paclitaxel-induced nuclear factor-κB pathway in
breast cancer cells and inhibits lung metastasis of human breast
cancer in nude mice. Clin Cancer Res. 11:7490–7498. 2005.
|
|
13.
|
Bachmeier B, Nerlich AG, Iancu CM, Cilli
M, Schleicher E, Vené R, Dell’Eva R, Jochum M, Albini A and Pfeffer
U: The chemopreventive polyphenol curcumin prevents hematogenous
breast cancer metastases in immunodeficient mice. Cell Physiol
Biochem. 19:137–152. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Harikumar KB, Kuttan G and Kuttan R:
Inhibition of progression of erythroleukemia induced by Friend
virus in BALB/c mice by natural products - berberine, curcumin and
picroliv. J Exp Ther Oncol. 7:275–284. 2008.PubMed/NCBI
|
|
15.
|
William BM, Goodrich A, Peng C and Li S:
Curcumin inhibits proliferation and induces apoptosis of leukemic
cells expressing wild-type or T315I-BCR-ABL and prolongs survival
of mice with acute lymphoblastic leukemia. Hematol. 13:333–343.
2008. View Article : Google Scholar
|
|
16.
|
Faderl S, Kantarjian HM, Talpaz M and
Estrov Z: Clinical significance of cytogenetic abnormalities in
adult acute lymphoblastic leukemia. Blood. 91:3995–4019.
1998.PubMed/NCBI
|
|
17.
|
Greaves MF and Wiemels J: Origins of
chromosome translocations in childhood leukaemia. Nat Rev Cancer.
3:639–649. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Greil J, Gramatzki M, Burger R, Marschalek
R, Peltner M, Trautmann U, Hansen-Hagge TE, Bartram CR, Fey GH,
Stehr K, et al: The acute lymphoblastic leukaemia cell line SEM
with t(4;11) chromosomal rearrangement is biphenotypic and
responsive to interleukin-7. Br J Haematol. 86:275–283. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Zunino SJ, Storms DH, Newman JW, Pedersen
TL, Keen CL and Ducore JM: Resveratrol given intraperitoneally does
not inhibit the growth of high-risk t(4;11) acute lymphoblastic
leukemia cells in a NOD/SCID mouse model. Int J Oncol.
40:1277–1284. 2012.PubMed/NCBI
|
|
20.
|
Lock RB, Liem N, Farnsworth ML, Milross
CG, Xue C, Tajbakhsh M, Haber M, Norris MD, Marshall GM and Rice
AM: The nonobese diabetic/severe combined immunodeficient
(NOD/SCID) mouse model of childhood acute lymphoblastic leukemia
reveals intrinsic differences in biologic characteristics at
diagnosis and relapse. Blood. 99:4100–4108. 2002. View Article : Google Scholar
|
|
21.
|
Liem NL, Papa RA, Milross CG, Schmid MA,
Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD,
MacKenzie KL and Lock RB: Characterization of childhood acute
lymphoblastic leukemia xenograft models for the preclinical
evaluation of new therapies. Blood. 103:3905–3914. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Gaedeke J, Noble NA and Border WA:
Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through
up-regulation of heme oxygenase 1. Kidney Int. 68:2042–2049. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
United States Department of Health and
Human Services, Food and Drug Administration. Center for Veterinary
Medicine: Guidance for Industry Validation of Analytical Procedures
for Type C Medicated Feeds. #135. pp. 1–14. 2005, http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm052530.pdf.
|
|
24.
|
Zunino SJ, Storms DH, Newman JW, Pedersen
TL, Keen CL and Ducore JM: Dietary resveratrol does not delay
engraftment, sensitize to vincristine or inhibit growth of
high-risk acute lymphoblastic leukemia cells in NOD/SCID mice. Int
J Oncol. 41:2207–2212. 2012.PubMed/NCBI
|
|
25.
|
Sharma RA, Euden SA, Platton SL, Cooke DN,
Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer
SM, Pirmohamed M, Gescher AJ and Steward WP: Phase I clinical trial
of oral curcumin: biomarkers of systemic activity and compliance.
Clin Cancer Res. 10:6847–6854. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Sharma RA, Gescher AJ and Steward WP:
Curcumin: the story so far. Eur J Cancer. 41:1955–1968. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Lao CD, Ruffin MT IV, Normolle D, Heath
DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL and Brenner
DE: Dose escalation of a curcuminoid formulation. BMC Complement
Altern Med. 6:102006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Ravindranath V and Chandrasekhara N:
Metabolism of curcumin - studies with [3H] curcumin.
Toxicol. 22:337–344. 1982.
|
|
29.
|
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF,
Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen
GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and
Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive
agent, in patients with high-risk or premalignant lesions.
Anticancer Res. 21:2895–2900. 2001.PubMed/NCBI
|
|
30.
|
Vareed SK, Kakarala M, Ruffin MT, Crowell
JA, Normolle DP, Djuric Z and Breener DE: Pharmacokinetics of
curcumin conjugate metabolites in healthy human subjects. Cancer
Epidemiol Biomarkers Prev. 17:1411–1417. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Carroll RE, Benya RV, Turgeon DK, Vareed
S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C,
Meyskens FL Jr and Brenner DE: Phase IIa clinical trial of curcumin
for the prevention of colorectal neoplasia. Cancer Prev Res
(Phila). 4:354–364. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Hanai H, Iida T, Takeuchi K, Watanabe F,
Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M,
Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii
S, Uchijima M, Nagata T and Koide Y: Curcumin maintenance therapy
for ulcerative colitis: randomized, mulicenter, double-blind,
placebo-controlled trial. Clin Gastroenterol Hepatol. 4:1502–1506.
2006. View Article : Google Scholar
|
|
33.
|
Dhillon N, Aggarwal BB, Newman RA, Wolff
RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock
R: Phase II trial of curcumin in patients with advanced pancreatic
cancer. Clin Cancer Res. 14:4491–4499. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Yallapu MM, Jaggi M and Chauhan SC:
Curcumin nanoformulations: a future nanomedicine for cancer. Drug
Discov Today. 17:71–80. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang
Y, Wang H, Zhou Q and Yu S: PLGA nanoparticles improve the oral
bioavailability of curcumin in rats: characterizations and
mechanisms. J Agric Food Chem. 59:9280–9289. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Zhongfa L, Chiu M, Wang J, Chen W, Yen W,
Fan-Havard P, Yee LD and Chan KK: Enhancement of curcumin oral
absorption and pharmacokinetics of curcuminoids and curcumin
metabolites in mice. Cancer Chemother Pharmacol. 69:679–689. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Goel A and Aggarwal BB: Curcumin, the
golden spice from Indian saffron, is a chemosensitizer and
radiosensitizer for tumors and chemoprotector and radioprotector
for normal organs. Nutr Cancer. 62:919–930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Sreekanth CN, Bava SV, Sreekumar E and
Anto RJ: Molecular evidences for the chemosensitizing efficacy of
liposomal curcumin in paclitaxel chemotherapy in mouse models of
cervical cancer. Oncogene. 30:3139–3152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Ganta S, Devalapally H and Amiji M:
Curcumin enhances oral bioavailability and anti-tumor therapeutic
efficacy of paclitaxel upon administration in nanoemulsion
formulation. J Pharm Sci. 99:4630–4641. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Zunino SJ, Storms DH and Ducore JM: Novel
in vivo model of inducible multi-drug resistance in acute
lymphoblastic leukemia with chromosomal translocation t(4;11).
Cancer Lett. 296:49–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Nachman JB, Sather HN, Sensel MG, Trigg
ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM and Gaynon PS:
Augmented post-induction therapy for children with high-risk acute
lymphoblastic leukemia and a slow response to initial therapy. N
Engl J Med. 338:1663–1671. 1998. View Article : Google Scholar : PubMed/NCBI
|
